FINWIRES · TerminalLIVE
FINWIRES

瑞士股市本週收漲;博薩爾股價上漲

-- 週五,瑞士藍籌股指數收漲0.18%,投資人在對本週末即將舉行的美伊和平談判保持謹慎樂觀的同時,也評估最新的經濟相關動態。 KOF瑞士經濟研究所的全球經濟晴雨表在4月出現分化,同步晴雨表下降0.2點至102.1點,而領先晴雨表上升1.7點至102.9點。 「儘管3月份伊朗戰爭和霍爾木茲海峽關閉佔據了新聞頭條,但這兩個全球指標的波動幅度相對較小。兩個指標均略高於平均水平,」KOF主任揚-埃格伯特·施圖姆表示。 “目前看來,受訪者認為這場戰爭將是暫時的,而且主要局限於地區範圍,因此不會對他們的經濟狀況產生太大影響。” 在關稅方面,根據彭博新聞社援引匿名消息人士報道,瑞士正尋求在7月底前與美國達成貿易協議,瑞士政府預計今年4月舉行第三輪談判。 同時,政府數據顯示,瑞士消費者信心指數從2月的-30.4點降至3月的-42.9點。去年同期,該指數為-34.8點。瑞士聯邦經濟事務秘書處表示,經濟和金融前景指數以及購買大宗商品的時機指數年均有所惡化,而過去財務狀況指數幾乎沒有變化。 企業方面,博薩德集團(BOSN.SW)公佈,第一季集團淨銷售額年增至2.849億瑞士法郎,高於去年同期的2.833億瑞士法郎。這家瑞士工業緊固和組裝技術公司表示,儘管當前市場波動,且預計2026年上半年經濟需求疲軟,但公司仍致力於實現其中期財務目標。該股收盤上漲6.48%。 瑞銀集團(UBSG.SW)股價也上漲0.96%,此前瑞士聯邦刑事法院駁回了針對瑞銀集團的洗錢指控,該指控與瑞士信貸向莫三比克國有企業發放貸款有關。法院裁定,刑事責任不轉移至瑞銀集團,瑞銀集團於2023年收購了瑞士信貸。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB